Royalty Pharma plc - SIC # 6794 - PATENT OWNERS AND LESSORS

Ticker Exchange SIC # Website Latest Ticker
RPRX Nasdaq 6794 www.royaltypharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Royalty Pharma plc

Royalty Pharma declares third quarter 2026 dividend - Jul 17th, 2026 2:15 pm
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 - Jul 15th, 2026 2:15 pm
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again - Jul 10th, 2026 10:10 am
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice - Jul 10th, 2026 10:00 am
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run? - Jul 10th, 2026 7:15 am
RPRX or ACAD: Which Is the Better Value Stock Right Now? - Jul 9th, 2026 9:40 am
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight - Jul 9th, 2026 8:31 am
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat - Jun 29th, 2026 7:16 am
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Jun 15th, 2026 10:28 am
This Royalty Pharma Insider Reduced Their Stake By 10% - Jun 12th, 2026 8:00 am
3 Unpopular Stocks We’re Skeptical Of - Jun 12th, 2026 6:13 am
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report? - Jun 10th, 2026 9:30 am
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? - Jun 9th, 2026 8:06 am
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 4th, 2026 2:15 pm
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean - May 29th, 2026 6:34 pm
Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential - May 25th, 2026 5:11 pm
3 Mid-Cap Stocks We Steer Clear Of - May 20th, 2026 4:04 am
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance - May 18th, 2026 6:32 am
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions - May 16th, 2026 3:24 am
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - May 12th, 2026 2:15 pm